Research Papers:

Blocking the PAH2 domain of Sin3A inhibits tumorigenesis and confers retinoid sensitivity in triple negative breast cancer

Nidhi Bansal, Almudena Bosch, Boris Leibovitch, Lutecia Pereira, Elena Cubedo, Jianshi Yu, Keely Pierzchalski, Jace W. Jones, Melissa Fishel, Maureen Kane, Arthur Zelent, Samuel Waxman and Eduardo Farias _

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2016; 7:43689-43702. https://doi.org/10.18632/oncotarget.9905

Metrics: PDF 2350 views  |   HTML 2409 views  |   ?  


Nidhi Bansal1, Almudena Bosch1,*, Boris Leibovitch1,*, Lutecia Pereira2, Elena Cubedo2, Jianshi Yu3, Keely Pierzchalski3, Jace W. Jones3, Melissa Fishel1, Maureen Kane3, Arthur Zelent2, Samuel Waxman1, Eduardo Farias1

1The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA

2Division of Hemato-Oncology, Department of Medicine, Sylvester Comprehensive Cancer Center, Miller School of Medicine, University of Miami, Miami, FL, USA

3Department of Pharmaceutical Sciences, University of Maryland, School of Pharmacy, Baltimore, MD, USA

*These authors contributed equally to this work

Correspondence to:

Samuel Waxman, email: [email protected]

Eduardo Farias, email: [email protected]

Keywords: Sin3A, SID decoys, triple negative breast cancer, retinoids, metastases

Received: March 11, 2016     Accepted: May 05, 2016     Published: June 07, 2016


Triple negative breast cancer (TNBC) frequently relapses locally, regionally or as systemic metastases. Development of targeted therapy that offers significant survival benefit in TNBC is an unmet clinical need. We have previously reported that blocking interactions between PAH2 domain of chromatin regulator Sin3A and the Sin3 interaction domain (SID) containing proteins by SID decoys result in EMT reversal, and re-expression of genes associated with differentiation. Here we report a novel and therapeutically relevant combinatorial use of SID decoys. SID decoys activate RARα/β pathways that are enhanced in combination with RARα-selective agonist AM80 to induce morphogenesis and inhibit tumorsphere formation. These findings correlate with inhibition of mammary hyperplasia and a significant increase in tumor-free survival in MMTV-Myc oncomice treated with a small molecule mimetic of SID (C16). Further, in two well-established mouse TNBC models we show that treatment with C16-AM80 combination has marked anti-tumor effects, prevents lung metastases and seeding of tumor cells to bone marrow. This correlated to a remarkable 100% increase in disease-free survival with a possibility of “cure” in mice bearing a TNBC-like tumor. Targeting Sin3A by C16 alone or in combination with AM80 may thus be a promising adjuvant therapy for treating or preventing metastatic TNBC.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 9905